The activities of BAL9141 (formerly Ro 63-9141), a novel pyrrolidinone-3-ylidenemethyl cephalosporin, against 244 strains of gram-negative nonfermenters were evaluated. The overall MIC at which 50% of isolates are inhibited (MIC 50 ) and the overall MIC 90 were 2 and 64 g/ml, respectively, which are similar to those of imipenem, lower than those of the other cephalosporins tested, amoxicillin, and the ticarcillin-clavulanic acid combination, and much higher than those of ciprofloxacin. BAL9141 shows species-dependent activity in vitro against a variety of gram-negative nonfermentative pathogens.
BAL9141 (formerly Ro 63-9141) is a novel pyrrolidinone-3-ylidenemethyl cephalosporin that consistently has activity against methicillin-resistant strains of Staphylococcus spp. but that exhibits promising in vitro and in vivo activities against a variety of gram-negative pathogens (1) . The purpose of this study was to evaluate the activity of BAL9141 against a broad range of aerobic gram-negative glucose-nonfermentative rods.
(Part of this work was presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., 1998 [R. Zbinden, V. Puenter, and A. von Graevenitz, Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-19, 1998 ].).
The MICs of BAL9141 and nine other antimicrobials were determined by the NCCLS agar dilution method on non-cation-adjusted Mueller-Hinton agar (Becton Dickinson Microbiology Systems, Cockeysville, Md.) for 244 gram-negative nonfermenters that were collected through 1995 in the Department of Medical Microbiology, University of Zurich, Zurich, Switzerland, and a reference strain, Pseudomonas aeruginosa ATCC 27853 (5) . A 0.5 McFarland suspension in phosphatebuffered saline was diluted 1/10 to obtain the desired inoculum of 10 7 CFU/ml. A multipoint inoculator was used to deliver 10 4 CFU per spot to each test plate and to control plates without antibiotics. Cultures were incubated at 35°C for 20 h in an aerobic atmosphere in accordance with the NCCLS methodology (5). BAL9141 of known potency was supplied by F. Hoffmann-La Roche, Basel, Switzerland (courtesy of P. Hebeisen). The other compounds were obtained from commercial sources. Identification of the isolates studied was in accordance with recommended methods (4). The MICs of BAL9141 and the other antimicrobial agents are shown in Table 1 . The modal MIC of BAL9141 for P. aeruginosa ATCC 27853 was 2 g/ml; the MICs of the other antimicrobial agents for P. aeruginosa fell within expected ranges (6) . The MICs at which 50% of isolates are inhibited (MIC 50 s) and MIC 90 s for all 244 strains were 2 and 64 g/ml, respectively, for BAL9141; 8 and 64 g/ml, respectively, for cefepime; 64 and Ͼ64 g/ml, respectively, for cefotetan; 8 and Ͼ64 g/ml, respectively, for cefozopran; 8 and Ͼ64 g/ml, respectively, for ceftazidime; 8 and Ͼ64 g/ml, respectively, for ceftriaxone; 32 and Ͼ64 g/ml, respectively, for amoxicillinclavulanic acid; 32 and Ͼ64 g/ml, respectively, for ticarcillinclavulanic acid; 1 and 64 g/ml, respectively, for imipenem; and 0.25 and 4 g/ml, respectively, for ciprofloxacin. Ta (7), and von Graevenitz and Bucher (8) .
The overall activities of BAL9141 against the glucose-nonfermentative gram-negative rods tested were most similar to those of imipenem in terms of MIC 50 s and MIC 90 s. Imipenem, however, had clearly superior activity against Achromobacter xylosoxidans, Acinetobacter baumannii, Brevundimonas vesicularis, Burkholderia cepacia, Comamonas acidovorans, P. aeruginosa, Pseudomonas stutzeri, and W. virosa. For the other species tested, their activities were similar. Cefepime was more active against Chryseobacterium indologenes and Sphingomonas spp. and, to some extent, was also more active against P. aeruginosa. Cefozopran was, overall, as active as cefepime. With the exception of ceftazidime against B. cepacia, C. acidovorans, and P. aeruginosa, the expanded-spectrum and broad-spectrum cephalosporins were less active than BAL9141 or the penicillin-clavulanic acid combinations.
While imipenem and ciprofloxacin have greater potencies against most of the organisms tested, BAL9141, cefepime, and cefozopran, in decreasing order, appear to be potent enough to a NCCLS-approved susceptibility breakpoint for P. aeruginosa and other nonmembers of the family Enterobacteriaceae (6), 8 g/ml.
b NCCLS-approved susceptibility breakpoint for ampicillin-sulbactam (6), 8/4 g/ml.
c NCCLS-approved susceptibility breakpoint for nonmembers of the family Enterobacteriaceae, 16/2 g/ml; NCCLS-approved susceptibility breakpoint for P. aeruginosa, 64/2 g/ml.
d NCCLS-approved susceptibility breakpoint for P. aeruginosa and other nonmembers of the family Enterobacteriaceae (6), 4 g/ml.
e NCCLS-approved susceptibility breakpoint (6), 1 g/ml.
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